Lisaftoclax( Bcl-2/Bcl-xl inhibitor 1 | APG-2575 )

Catalog No. M26069 CAS No. 2180923-05-9

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Lisaftoclax
Note

Research use only, not for human use.
Brief Description

Bcl-2/Bcl-xl inhibitor 1 is a dual Bcl-2 and Bcl-xl inhibitor (IC50s: 2 nM and 5.9 nM for Bcl-2 and Bcl-xl) with anti-tumor activity. It is extracted from patent WO2018027097A1.
Description

Bcl-2/Bcl-xl inhibitor 1 is a dual Bcl-2 and Bcl-xl inhibitor (IC50s: 2 nM and 5.9 nM for Bcl-2 and Bcl-xl) with anti-tumor activity. It is extracted from patent WO2018027097A1.(In Vitro):Lisaftoclax shows IC50s of 5.5 nM and 6.4 nM in Bcl-2 dependent RS4 11 cells and Bcl-xl dependent Molm 13 cells.
In Vitro

Lisaftoclax (compound 6) exhibits IC50 values of 5.5 nM and 6.4 nM in Bcl-2 dependent RS4;11 cells and Bcl-xl dependent Molm13 cells.
In Vivo

——
Synonyms

Bcl-2/Bcl-xl inhibitor 1 | APG-2575
Pathway

Angiogenesis
Target

Bcl-2
Recptor

E3 ligase ligand-linker conjugate
Research Area

——
Indication

——

CAS Number

2180923-05-9
Formula Weight

882.43
Molecular Formula

C45H48ClN7O8S
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 100 mg/mL (113.32 mM)
SMILES

[O-][N+](=O)c1cc(ccc1NC[C@H]1COCCO1)S(=O)(=O)NC(=O)c1ccc(cc1Oc1cnc2[nH]ccc2c1)N1CCN(CC2=C(CC3(CCC3)CC2)c2ccc(Cl)cc2)CC1
Chemical Name

——